(Q80270243)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Stefano Necozione

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Silvio Rea

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Francesco Recchia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Gaetano Saggio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Giovanna Amiconi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Anna Di Blasio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Alisia Cesta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Giampiero Candeloro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Giovanni Mantovani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

3 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

164-169

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Anthracyclines in the treatment of gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Impact of doxorubicin on survival in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Oxaliplatin: a review of preclinical and clinical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Second-line treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Recurrent ovarian cancer: how important is it to treat to disease progression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase I study of oxaliplatin in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.015

10.1016/J.YGYNO.2007.03.015

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481704%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference